Terumo Corporation

DB:TUO Stock Report

Market Cap: €28.4b

Terumo Valuation

Is TUO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TUO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TUO (€19.1) is trading above our estimate of fair value (€18.17)

Significantly Below Fair Value: TUO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TUO?

Key metric: As TUO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TUO. This is calculated by dividing TUO's market cap by their current earnings.
What is TUO's PE Ratio?
PE Ratio38.5x
EarningsJP¥119.49b
Market CapJP¥4.60t

Price to Earnings Ratio vs Peers

How does TUO's PE Ratio compare to its peers?

The above table shows the PE ratio for TUO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.6x
SHL Siemens Healthineers
29.1x14.2%€56.5b
AFX Carl Zeiss Meditec
25.4x16.3%€5.2b
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
TUO Terumo
38.5x12.1%€4.6t

Price-To-Earnings vs Peers: TUO is expensive based on its Price-To-Earnings Ratio (38.5x) compared to the peer average (21.6x).

Price to Earnings Ratio vs Industry

How does TUO's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
TUO 38.5xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TUO is expensive based on its Price-To-Earnings Ratio (38.5x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is TUO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TUO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.5x
Fair PE Ratio29.3x

Price-To-Earnings vs Fair Ratio: TUO is expensive based on its Price-To-Earnings Ratio (38.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TUO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€19.10
€20.73
+8.5%
9.7%€23.55€15.45n/a14
Nov ’25€17.10
€20.02
+17.1%
9.8%€22.76€15.38n/a14
Oct ’25€17.00
€20.23
+19.0%
10.0%€23.03€15.56n/a14
Sep ’25€16.50
€19.90
+20.6%
10.4%€22.90€15.47n/a13
Aug ’25€16.20
€18.86
+16.4%
10.3%€21.60€15.00n/a13
Jul ’25€14.50
€18.22
+25.6%
10.3%€21.20€14.72n/a13
Jun ’25€15.60
€18.14
+16.3%
10.5%€21.19€14.72n/a13
May ’25€15.90
€18.01
+13.2%
12.6%€21.66€14.95n/a12
Apr ’25€16.70
€18.10
+8.4%
13.2%€22.00€15.18n/a12
Mar ’25€18.00
€17.58
-2.3%
12.9%€21.82€15.06n/a12
Feb ’25€15.60
€16.15
+3.5%
9.1%€19.36€13.43n/a12
Jan ’25€14.50
€16.40
+13.1%
11.4%€20.64€13.70n/a12
Dec ’24€14.50
€15.69
+8.2%
10.5%€19.83€13.17n/a13
Nov ’24€12.90
€15.33
+18.8%
13.1%€20.18€11.98€17.1013
Oct ’24€12.60
€15.09
+19.8%
9.9%€17.10€12.03€17.0010
Sep ’24€13.90
€15.24
+9.6%
10.2%€17.38€12.01€16.5011
Aug ’24€14.80
€15.59
+5.3%
9.0%€17.58€12.46€16.2011
Jul ’24€14.30
€15.98
+11.7%
10.5%€18.31€12.32€14.5012
Jun ’24€14.40
€16.30
+13.2%
15.6%€22.77€12.39€15.6013
May ’24€13.50
€16.15
+19.7%
16.8%€22.65€10.99€15.9013
Apr ’24€12.40
€17.13
+38.2%
17.5%€24.67€11.63€16.7013
Mar ’24€12.30
€16.98
+38.1%
17.0%€24.10€11.36€18.0014
Feb ’24€13.40
€18.13
+35.3%
12.8%€24.45€14.53€15.6014
Jan ’24€13.30
€18.34
+37.9%
13.7%€25.87€14.88€14.5014
Dec ’23€14.30
€17.90
+25.1%
13.9%€25.21€14.85€14.5014
Nov ’23€15.30
€18.21
+19.0%
13.8%€25.62€15.09€12.9014

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%